Cargando…
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice
CD137 is an attractive target for cancer immunotherapy, but its expression in normal tissues induces some adverse effects in patients receiving CD137-targeted therapy. To overcome this issue, we developed a switch antibody, STA551, that binds to CD137 only under high ATP concentrations around cells....
Autores principales: | Sugyo, Aya, Tsuji, Atsushi B, Sudo, Hitomi, Narita, Yoshinori, Taniguchi, Kenji, Nemoto, Takayuki, Isomura, Fumihisa, Awaya, Norihiro, Kamata-Sakurai, Mika, Higashi, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284450/ https://www.ncbi.nlm.nih.gov/pubmed/35820360 http://dx.doi.org/10.1016/j.tranon.2022.101481 |
Ejemplares similares
-
In vivo imaging with two-photon microscopy to assess the tumor-selective binding of an anti-CD137 switch antibody
por: Kaneko, Chisato, et al.
Publicado: (2022) -
CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009) -
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)